

<b>NCT ID</b>	NCT06455254
<b>Title</b>	Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM
<b>Phase</b>	Phase 2
<b>Date Added</b>	2024-06-12
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06415851
<b>Title</b>	Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
<b>Phase</b>	Phase 2
<b>Date Added</b>	2024-05-15
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06412198
<b>Title</b>	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2024-05-14
<b>Location</b>	Massachusetts, United States Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Adagrasib, cemiplimab, cetuximab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06336902
<b>Title</b>	Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2024-03-29
<b>Location</b>	California, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Balstilimab, Botensilimab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06322693
<b>Title</b>	A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2024-03-21

Location	Arizona, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	District of Columbia, United States
	Florida, United States
	Georgia, United States
	Illinois, United States
	Iowa, United States
	Kansas, United States
	Kentucky, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	New Jersey, United States
	New York, United States
	Ohio, United States
	Oregon, United States
	Pennsylvania, United States
	South Carolina, United States
	Tennessee, United States
	Texas, United States
	Virginia, United States
	Washington, United States
	Wisconsin, United States
	Korea, Republic of
	Spain
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT06310564
Title	Low and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy
Phase	Not Applicable
Date Added	2024-03-15
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT06300463
Title	Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Phase	Phase 2
Date Added	2024-03-08
Location	New York, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	AGEN1423, Balstilimab, Botensilimab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06302062

<b>Title</b>	Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2024-03-08
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06253520
<b>Title</b>	Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2024-02-12
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Aldesleukin, Cyclophosphamide, Fludarabine
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06218914
<b>Title</b>	A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
<b>Phase</b>	Phase 1
<b>Date Added</b>	2024-01-23
<b>Location</b>	California, United States Florida, United States Illinois, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp